Randomized, Open-Label, Multicenter Study of Safety, Efficacy, and Tolerability of the Combination of RO5466731, RO5190591, Ritonavir, and Copegus With or Without RO5024048 in HCV Genotype 1 Infected Patients Who Are Either Treatment Naive or Null Responders to Previous Interferon-Based Treatment

Trial Profile

Randomized, Open-Label, Multicenter Study of Safety, Efficacy, and Tolerability of the Combination of RO5466731, RO5190591, Ritonavir, and Copegus With or Without RO5024048 in HCV Genotype 1 Infected Patients Who Are Either Treatment Naive or Null Responders to Previous Interferon-Based Treatment

Completed
Phase of Trial: Phase II

Latest Information Update: 01 Apr 2016

At a glance

  • Drugs Danoprevir (Primary) ; Mericitabine (Primary) ; Setrobuvir (Primary) ; Ribavirin; Ritonavir
  • Indications Hepatitis C
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms ANNAPURNA
  • Sponsors Roche
  • Most Recent Events

    • 13 Jan 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
    • 18 Jun 2013 Planned End Date changed from 1 Apr 2014 to 1 Dec 2013 as reported by ClinicalTrials.gov.
    • 18 Jun 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top